News
BNGOW
0.1075
+4.57%
0.0047
BRIEF-Bionano Announces First Study Using Ogm To Discover Structural Variants With Potential Relevance To Genetic Diagnosis Of Mrkh Syndrome, A Syndrome Impacting Reproductive System Development In 1 In 4,500 Females
Reuters · 03/22 12:12
BRIEF-Bionano Labs Expands Clinical Testing Menu With Launch Of OGM-Based LDTs
Reuters · 03/15 12:08
BRIEF-Bionano Genomics As Of March 10 Has About $2.1 Mln In Accounts With SVB
Reuters · 03/13 12:34
BRIEF-Bionano Genomics Inc Files For Mixed Shelf Offering Of Up To $400 Million - SEC Filing
Reuters · 03/10 21:27
BRIEF-Bionano Genomics Reports Fourth Quarter And Full-Year 2022 Results And Provides Revenue Outlook For 2023
Reuters · 03/09 21:57
BRIEF-Bionano Informs On China NMPA Approval
Reuters · 02/22 17:34
BRIEF-Bionano Announces Launch Of Next-Generation Versions Of Its Reagent Kits And Chip Consumable, Along With Updates To Its Instrument Control And Bionano Access Software
Reuters · 01/23 13:14
BRIEF-Bionano Announces Publication Of Interim Readout From Trial Analyzing Optical Genome Mapping As Potential Standard Of Care For Prenatal Testing
Reuters · 01/18 17:52
BRIEF-Bionano with NVIDIA To Accelerate Data Processing Solution For Optical Genome Mapping Workflow
Reuters · 01/12 13:42
BRIEF-Bionano Genomics Reports Q4 Revenue Of $7.9 Mln
Reuters · 01/05 13:55
BRIEF-Bionano Genomics To Acquire Purigen Biosystems
Reuters · 11/28/2022 22:04
Publication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate Cancer
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing optical genome mapping (OGM) to detect structural variants (SVs) and balanced rearrangements relevant to prostate cancer...
GlobeNewswire · 11/21/2022 13:00
Bionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress
– 55% year-over-year revenue growth in Q3 2022 – On track to achieve all 2022 ELEVATE! milestones – Strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities at the end of Q3 2022 – Conference call today, Novembe...
GlobeNewswire · 11/03/2022 20:01
Publication Recommends OGM for Analysis of Hematological Neoplasms Due to Streamlined Structural Variant Detection and High Concordance with Traditional Cytogenetic Methods
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the first published validation study to evaluate the performance of optical genome mapping (OGM) versus traditional cytogenetic techniques for the analysis o...
GlobeNewswire · 11/03/2022 12:00
BRIEF-Bionano Genomics Announces Extensive Lineup Of Content At Association For Molecular Pathology Annual Meeting
Reuters · 10/28/2022 12:12
Bionano Genomics Announces Global User Event at Bionano Laboratories Before American Society of Human Genetics (ASHG) Annual Meeting
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the company will host a “Meet the User” event today, October 24, 2022, at its new CLIA-certified Bionano Laboratories facility in advance of the American Soci...
GlobeNewswire · 10/24/2022 12:00
BRIEF-Bionano Genomics Announces Launch Of CLIA-Certified Bionano Laboratories
BRIEF-Bionano Genomics Announces Launch Of CLIA-Certified Bionano Laboratories
Reuters · 09/23/2022 12:14
Bionano Genomics Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss
SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing OGM to detect cryptic balanced chromosomal rearrangements (BCRs) found in subjects who experienced recurrent pregnancy ...
GlobeNewswire · 09/21/2022 12:00
BRIEF-Bionano Genomics Announces Study Demonstrating Utility Of OGM For Quality Evaluation Of Human Induced Pluripotent Stem Cells (IPSCS)
BRIEF-Bionano Genomics Announces Study Demonstrating Utility Of OGM For Quality Evaluation Of Human Induced Pluripotent Stem Cells (IPSCS)
Reuters · 09/08/2022 12:03
Bionano Genomics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) announced today that company management will participate virtually at the H.C. Wainwright 24th Annual Global Annual Global Investment Conference, taking place September 12-14, 2022...
GlobeNewswire · 09/07/2022 20:30
More
Webull provides a variety of real-time BNGOW stock news. You can receive the latest news about Bionano Genomics through multiple platforms. This information may help you make smarter investment decisions.
About BNGOW
Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.